Coave Therapeutics, a Paris, France-based genetic medicines company, raised €32M in Series A funding.
The round was led by Novo Holdings A/S and Bpifrance, with participation from Invus and UI Investissement, alongside existing investors Seroba Life Sciences, Fund+, Kurma Partners, Omnes Capital and Turenne Capital.
The company intends to use the funds to advance its proprietary ALIGATER™ platform to enhance targeting, specificity, efficacy and manufacturability of genetic medicines with broad clinical applications.
Led by CEO Rodolphe Clerval, Coave Therapeutics is a genetic medicine company providing the development of solutions to enhance the genetic medicines. With its proprietary ALIGATER™ platform, it is addressing challenges in gene therapy delivery to extra-hepatic tissues, creating a robust pipeline targeting CNS, neuromuscular and eye diseases.
In connection with the financing, Emmanuelle Coutanceau from Novo Holdings and Jean Francois Morin from Bpifrance will join Coave’s Board of Directors.
FinSMEs
09/01/2025